Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.

Journal of immunotherapy and precision oncology·2023
Same author

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.

Cancer·2023
Same author

Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors.

Cancer medicine·2022
Same author

Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors.

Scientific reports·2022
Same author

Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.

Clinical lung cancer·2022

Related Experiment Video

Updated: Jul 3, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Tumor lysis syndrome in solid tumors.

Frank E Mott1, Alex Esana, Carl Chakmakjian

  • 1Division of Hematology/Oncology, Scott & White Clinic, Temple, Texas.

Supportive Cancer Therapy
|July 17, 2008
PubMed
Summary

Tumor lysis syndrome (TLS) can occur in solid tumors, not just blood cancers. Early recognition and proactive management, including hydration and medication, are crucial for patient outcomes.

Area of Science:

  • Oncology
  • Nephrology
  • Internal Medicine

Background:

  • Tumor lysis syndrome (TLS) is a serious oncologic emergency characterized by metabolic derangements.
  • While commonly associated with hematologic malignancies, TLS in solid tumors is less frequently reported but can occur.
  • TLS can manifest as a complication of the disease itself or as a response to cancer treatment.

Purpose of the Study:

  • To highlight the occurrence of TLS in solid tumors.
  • To alert clinicians to the potential for TLS in patients with solid malignancies.
  • To emphasize the importance of preemptive management strategies for TLS in this patient population.

Main Methods:

  • Case series presentation of three patients with solid tumors who developed TLS.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Experiment Videos

Last Updated: Jul 3, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

  • Review of identified risk factors associated with TLS development in these cases.
  • Description of treatment interventions and patient responses.

    • Main Results:

    • Three cases of TLS were observed in patients with small-cell lung cancer and breast cancer upon treatment initiation.
    • Identified risk factors included large tumor burden, aggressive tumor biology, liver involvement, and pre-existing lab abnormalities.
    • All patients responded favorably to hydration and allopurinol; one patient also received rasburicase.

    Conclusions:

    • TLS can occur in solid tumors and may be underdiagnosed.
    • Clinicians should maintain a high index of suspicion for TLS in patients with solid tumors, particularly those with risk factors.
    • Prompt diagnosis and preemptive management are essential for effective TLS control in solid tumor patients.